

Medtronic Evolut Pro: System Overview

Eberhard Grube, MD, FACC, FSCAI
University Hospital, Dept of Medicine II, Bonn, Germany
Stanford University, Palo Alto, California, USA

Disclosure Eberhard Grube, MD

Speaker Bureau/Advisory Board:

Medtronic: C, SB, AB, OF
LivaNova: C, SB, AB
Highlife: AB, SB
Boston Scientific: C, SB, AB
Jena Valve: C, SB, AB
CardioMech: C, AB
Mitral Technology: C, SB,

AB

Equity Interest:

InSeal Medical: E, AB,
MTEx: E, AB, SB
Cardiovalve: E, SB,
Claret: E, AB
Shockwave: E, AB
Valve Medical: E, AB
Millipede E, AB, SB
Pie-Cardia: E, AB, SB
Imparative Medical: E, AB
Ancora: E, AB, SB

Key

G – Grant and or Research Support E – Equity Interests S – Salary, AB – Advisory Board
C – Consulting fees, Honoraria R – Royalty Income I – Intellectual Property Rights
SB – Speaker's Bureau O – Ownership OF – Other Financial Benefits'


PROVEN PLATFORM PERFORMANCE

MEDTRONIC COREVALVE™ AND EVOLUT™ SYSTEMS



Medtronic CoreValve and Evolut R Systems have an extensive history of proven platform performance:

- **> 120,000 Implants**
- **> 1,000 Centers**
- **> 100 Countries**



MEDTRONIC EVOLUT PRO SYSTEM

DESIGN GOALS


The Evolut PRO system is a next generation self-expanding transcatheter aortic valve (TAV) that is intended to achieve two primary performance goals:

- 1 Provide Advanced Sealing**
 - Greater surface area contact
 - Low PVL Rates
- 2 Maintain Proven Platform Performance**
 - Unsurpassed Hemodynamics
 - Control During Deployment
 - Low Delivery Profile



MEDTRONIC EVOLUT PRO SYSTEM


SYSTEM COMPONENTS



EVOLUT PLATFORM

INDICATED ANNULUS RANGE (MM)

Together, the Evolut PRO and Evolut R Systems treat the **widest annulus range** of any commercially available TAVR system*



| Evolut PRO TAV | | | | | | | | | | Evolut R TAV | | | | |
|----------------|------|----|-------|----|----|-------|----|----|------|--------------|----|----|------|--|
| 23 mm | | | 26 mm | | | 29 mm | | | | 34 mm | | | | |
| 17** | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | |
| 53.4** | 56.5 | | 62.8 | | | 72.3 | | | 81.7 | | | | 94.2 | |

* Based on CT measurement

**Measurement for TAV in SAV only. | † Annulus Perimeter = Annulus Diameter x π

EVOLUT PRO


DESIGN GOAL 1:

ADVANCED SEALING

EVOLUT PRO TRANSCATHETER VALVE


ADVANCED SEALING

Building on Proven Design for **Advanced Sealing**




Conformable Frame

Self-expanding nitinol frame conforms to annulus




CoreValve



Consistent Radial Force

Frame oversizing and cell geometry provide consistent radial force across treatable annulus range




Evolut R



External Wrap

External wrap increases surface contact with native anatomy



Evolut PRO

EVOLUT PRO

WRAP DESIGN AND CONSTRUCTION

- Evolut R TAV with added external porcine pericardial wrap
 - Identical frame and inner tissue as Evolut R
 - External wrap covers first 1½ inflow cells and extended skirt
- Sutures secure inner skirt and outer wrap together to the frame
 - Same number and location of sutures as Evolut R TAV




EVOLUT PRO EXTERNAL TISSUE WRAP

INCREASED SURFACE CONTACT WITH NATIVE ANATOMY

External Tissue Wrap **Increases Surface Contact** with Native Anatomy

- Surface contact between a transcatheter aortic valve and the native anatomy is critical for effective sealing
- Evolut PRO TAV's conforming frame and consistent radial force provide **contact at multiple levels**
- The external wrap provides added tissue volume between the TAV and native anatomy to help reduce gaps and **increase surface contact area**

Conforming Frame Seals at Multiple Levels*



Bright Green = Contact with Native Anatomy

External Wrap Helps **Reduce Gaps** to **Increase Surface Contact**




*Bench top evaluation of the frame contacting the annulus based on a CT analysis of 1 patient; Image Courtesy of Dr. Piazza and Prof. Lange, German Heart Center, Munich Germany
NOTE: Images are for illustrative purposes only and may not be indicative of clinical performance.

PORCINE PERICARDIAL TISSUE INTERACTION

Animal Studies Suggest Favorable Response and Interaction with Native Tissue

- Low inflammatory response¹
- **Stable and mature tissue growth** observed at 90 days post implant¹
 - Thin and even layer of endothelial cells on inner lumen of device



Evolut PRO explanted from Porcine Model at 60 Days
Cross Section between Nodes 1 and 2, example picture from MDT research study on file illustrating tissue interaction.²

1. Medtronic data on file. 90 day porcine GLP Evolut R study, results may not be indicative of clinical performance
2. Medtronic, data on file. 60 day porcine research study model, results may not be indicative of clinical performance.

EVOLUT PRO **DESIGN GOAL 2:** **PROVEN PLATFORM** **PERFORMANCE**

EVOLUT PRO SYSTEM

PROVEN PLATFORM PERFORMANCE



Evolut R TAV

Proven Platform Performance

- Supra-annular valve function provides **unsurpassed hemodynamics**
- **Controlled, accurate deployment** with the ability to recapture and reposition
- **Lowest delivery profile** with integrated InLine Sheath



Evolut PRO TAV

PROVEN PLATFORM PERFORMANCE

EVOLUT FAMILY TAV DESIGN

SUPRA ANNULAR VALVE DESIGN

- Maximizes leaflet coaptation
- Promotes single digit gradients and large EOAs



PORCINE PERICARDIAL TISSUE

- Thin for low profile delivery
- Strength and pliability for durability

SELF-EXPANDING FRAME

- Conforms and seals to the annulus
- The foundation for recapturability



PROVEN PLATFORM PERFORMANCE

CONTROLLED, ACCURATE DELIVERY WITH ABILITY TO RECAPTURE

EnVeo™ R 16Fr Equivalent DCS enables controlled **1:1 Response**
with ability to **Recapture**



LOWEST DELIVERY PROFILE

5.5MM ACCESS VESSEL REQUIREMENT

EnVeo R InLine™ Sheath allows treatment of trans-arterial access vessel diameters ≥ 5.5 mm across all Evolut PRO valve sizes



EVOLUT PRO DELIVERY CATHETER SYSTEM

DELIVERY PROFILE COMPARISON

Lowest delivery profile across **all valve sizes** with InLine Sheath

Evolut R 23/26/29 mm TAV

Evolut PRO /Evolut R 34 mm TAV

≥ 5.0 mm

Treatable Access
Vessel Diameter

≥ 5.5 mm



18 Fr OD

14 Fr Equivalent



20 Fr OD

16 Fr Equivalent

The Evolut System retains its outer diameter as it enters the vessel and remains at this diameter as it is advanced to the annulus.

EVOLUT PRO **CLINICAL PERFORMANCE**

EVOLUT PRO SYSTEM CLINICAL TRIAL

PATIENT CHARACTERISTICS

| Characteristic, mean \pm SD or % | N=60 |
|--------------------------------------|-----------------|
| Age, years | 83.3 \pm 7.2 |
| Female | 65.0 |
| BSA, m ² | 1.8 \pm 0.2 |
| STS – PROM, % | 6.4 \pm 3.9 |
| NYHA Class III or IV | 70.0 |
| Peripheral vascular disease | 43.3 |
| Atrial fibrillation / atrial flutter | 18.6 |
| Diabetes mellitus | 43.3 |
| Severe aortic calcification | 20.5 |
| LV ejection fraction, % | 58.9 \pm 12.4 |
| Pre-existing pacemaker | 15.0 |

Forrest, et al., ACC, 2017

EVOLUT PRO SYSTEM CLINICAL TRIAL


PROCEDURAL OUTCOMES

| Characteristic, % or mean \pm SD | N = 60 |
|-------------------------------------|---------------|
| General anesthesia | 58.3 |
| Iliofemoral access approach | 98.3 |
| Valve Size Implanted | |
| 26 mm | 40.0 |
| 29 mm | 60.0 |
| Pre-TAVR balloon dilation | 51.7 |
| Post-implant balloon dilation | 26.7 |
| Percentage of patients repositioned | 35.0 |
| Average implant depth, mm | 4.3 \pm 1.6 |

EVOLUT PRO SYSTEM CLINICAL TRIAL

ADVANCED SEALING

Low rates of PVL while maintaining
low rates of mortality, stroke, and need for pacemaker




Forrest, et al., ACC, 2017

EVOLUT PRO SYSTEM CLINICAL TRIAL

UNSURPASSED HEMODYNAMIC PERFORMANCE

Supra-annular valve function provides **single-digit gradients** and **large effective orifice areas**




Forrest, et al., ACC, 2017

EVOLUT PRO CLINICAL TRIAL

SYMPTOMATIC IMPROVEMENT

87.9% of survivors **improved NYHA class** at 30 days







Forrest, et al., ACC, 2017

EVOLUT PRO **TRANSFEMORAL** **PROCEDURE &** **CASE EXAMPLE**

EVOLUT PRO/ EVOLUT R PATIENT SELECTION

AORTIC ROOT CRITERIA


| Valve Size Selection | Evolut PRO TAV | | | Evolut R TAV |
|--------------------------------------------|-----------------------------------------------------------------------------------|------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| |  |  |  |  |
| Size | 23 mm | 26 mm | 29 mm | 34 mm |
| Annulus Diameter | 17*/18 – 20 mm | 20 – 23 mm | 23 – 26 mm | 26 - 30 mm |
| Annulus Perimeter ($\pi \times$ Diameter) | 53.4*/ 56.5 – 62.8 mm | 62.8 – 72.3 mm | 72.3 – 81.7 mm | 81.7 – 94.2 mm |
| Sinus of Valsalva Diameter (Mean) | ≥ 25 mm | ≥ 27 mm | ≥ 29 mm | ≥ 31 mm |
| Sinus of Valsalva Height (Mean) | ≥ 15 mm | | | ≥ 16 mm |

* Measure for TAV in SAV only

EVOLUT PRO PROCEDURE


PROCEDURE OVERVIEW

Controlled, Accurate Deployment via Familiar Evolut Procedure and Best Practices



EVOLUT PRO CASE EXAMPLE

AORTIC ROOT MEASUREMENTS



35% cardiac phase

Ao Annulus mean diameter 21.2 mm

23.8 x 18.6

Major x Minor aortic annulus diameter

67.0

Aortic Annulus perimeter (21.3 x 3.14)

34.8

Max Ascending Aorta diameter

28.4 – 29.0

Sinus of Valsalva diameter (Mean 28.6)

20.2 – 20.8


Sinus of Valsalva height (Mean 20.5)

25.9 – 26.9


Sinotubular Junction Diameter (STJ)

Sinus Height


Left Coronary Cusp



Right Coronary Cusp




Non Coronary Cusp



SOV diameter

60% cardiac phase






LVOT



EVOLUT PRO CASE EXAMPLE

ACCESS MEASUREMENT AND ASSESSMENT

Clinical Analyst's Image



7.6 x 8.9

RFA min. diameter

7.7 x 8.3



RIA min. diameter

8.1 x 8.1

LFA min. diameter




7.5 x 8.1

LIA min. diameter




EVOLUT PRO CASE EXAMPLE

ANNULAR AND LVOT CALCIFICATION ASSESSMENT



EVOLUT PRO CASE EXAMPLE


SYSTEM TRACKING



EVOLUT PRO CASE EXAMPLE

VALVE DEPLOYMENT TO POINT OF NO RECAPTURE

Controlled, 1:1 Response with **Ability to Recapture***




*Able to recapture up to three times before reaching the point of no recapture; upon third recapture the system must be removed from the patient and replaced with a new delivery system and TAV.

EVOLUT PRO CASE EXAMPLE

VALVE RELEASE AND ASSESSMENT



Conformable frame, Consistent Radial Force, and External Wrap for **Advanced Sealing**



EVOLUT PRO CASE: LVOT CALCIFICATION

AR AT DISCHARGE AND 30 DAYS

Unsurpassed Hemodynamics



Site Reported AR*:

- Discharge = **None**
- 30 Days = **None**

▪ *Represents one case only and may not be indicative of clinical performance in other patients.


MEDTRONIC EVOLUT PRO SYSTEM SUMMARY

Intended for Advanced Sealing

- Conforming frame and consistent radial force provide contact at multiple levels in various annulus shapes
- External tissue wrap increases surface contact area

Proven Platform Performance

- Controlled, accurate deployment with the ability to recapture
- Supra-annular valve function provides unsurpassed hemodynamics
- Lowest delivery profile with integrated InLine Sheath



Thank you for your kind attention!